ÂÜÀòÂÒÂ×

John Berriman has significant experience in the biotech industry. He is currently Chairman of ReNeuron Group plc, Autifony Therapeutics Ltd. and Depixus SAS; and a non-executive director of Autolus Ltd. He has served as Chairman of Heptares Therapeutics Ltd. (sold to Sosei in February 2015) and Algeta ASA (sold to Bayer AG in 2014) and was a director of Micromet Inc. until its sale to Amgen in 2012. Previously he was a director of Abingworth Management where he was involved in founding, financing and serving as a director of several biotechnology companies in Europe and the USA, many of which obtained listings on public stock exchanges. Prior to that, John spent 14 years with Celltech Group plc and was a member of its Board when it listed on the London Stock Exchange in 1994. He has a degree in Chemical Engineering from the University of Cambridge and an MBA from the London Business School.​